[go: up one dir, main page]

WO2021213558A3 - Nucléoprotéine virale et formulations la contenant - Google Patents

Nucléoprotéine virale et formulations la contenant Download PDF

Info

Publication number
WO2021213558A3
WO2021213558A3 PCT/CU2021/050002 CU2021050002W WO2021213558A3 WO 2021213558 A3 WO2021213558 A3 WO 2021213558A3 CU 2021050002 W CU2021050002 W CU 2021050002W WO 2021213558 A3 WO2021213558 A3 WO 2021213558A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleoprotein
rna
relates
infectious
mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CU2021/050002
Other languages
English (en)
Spanish (es)
Other versions
WO2021213558A2 (fr
Inventor
Julio César AGUILAR RUBIDO
Jorge Agustín AGUIAR SANTIAGO
Maarten VAN-DE-KLUNDERT
Martin KÄCHELE
Fazle Akbar SHEIKH MOHAMMAD
Mamun AL-MAHTAB
Gerardo Enrique Guillen Nieto
Helal UDDIN
Frank Thiele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority to JP2022563491A priority Critical patent/JP2023522118A/ja
Priority to CN202180043563.7A priority patent/CN115697394A/zh
Priority to MX2022013148A priority patent/MX2022013148A/es
Publication of WO2021213558A2 publication Critical patent/WO2021213558A2/fr
Publication of WO2021213558A3 publication Critical patent/WO2021213558A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un nucléoprotéine qui comprend un acide ribonucléique (ARN) et une protéine d'origine virale, la teneur en ARN étant supérieure de 20% (masse : masse) et ledit ARN étant protégé de la dégradation à l'intérieur d'une structure similaire à un virus, et ladite nucléoprotéine activant simultanément les récepteurs de l'immunité innée TLR3,TLR2, TLR7, TLR8 et TLR9. L'utilisation de ladite nucléoprotéine pour la fabrication de médicaments qui potentialisent une réponse anti-infectieuse, anti-tumorale ou anti-allergique, ou pour l'activation et l'entraînement de l'immunité innée dans la prévention ou le traitement de procédés infectieux ou allergiques. Cette nucléoprotéine peut être utilisée dans des traitements combinés avec d'autres médicaments. L'invention concerne également l'utilisation de la nucléoprotéine pour la fabrication d'un adjuvant ou un support d'antigènes vaccinaux, la formulation pharmaceutique comprenant la nucléoprotéine et un kit pour son administration mucosale.
PCT/CU2021/050002 2020-04-20 2021-04-16 Nucléoprotéine virale et formulations la contenant Ceased WO2021213558A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022563491A JP2023522118A (ja) 2020-04-20 2021-04-16 ウイルス核タンパク質及びその製剤
CN202180043563.7A CN115697394A (zh) 2020-04-20 2021-04-16 病毒核蛋白和包含其的制剂
MX2022013148A MX2022013148A (es) 2020-04-20 2021-04-16 Nucleoproteina viral y formulaciones que la contienen.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2020-0028 2020-04-20
CU2020000028A CU20200028A7 (es) 2020-04-20 2020-04-20 Nucleoproteína viral y formulaciones que la contienen

Publications (2)

Publication Number Publication Date
WO2021213558A2 WO2021213558A2 (fr) 2021-10-28
WO2021213558A3 true WO2021213558A3 (fr) 2021-12-30

Family

ID=77338444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2021/050002 Ceased WO2021213558A2 (fr) 2020-04-20 2021-04-16 Nucléoprotéine virale et formulations la contenant

Country Status (5)

Country Link
JP (1) JP2023522118A (fr)
CN (1) CN115697394A (fr)
CU (1) CU20200028A7 (fr)
MX (1) MX2022013148A (fr)
WO (1) WO2021213558A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202204803D0 (en) * 2022-04-01 2022-05-18 Univ Manchester Virus-like particles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009197001A (ja) * 2001-09-14 2009-09-03 Cytos Biotechnology Ag ウィルス様粒子中への免疫賦活物質のパッケージ化：調製法および使用法
WO2011057267A1 (fr) * 2009-11-09 2011-05-12 National Jewish Health Composition de vaccin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24454B1 (es) 2016-03-31 2019-11-04 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009197001A (ja) * 2001-09-14 2009-09-03 Cytos Biotechnology Ag ウィルス様粒子中への免疫賦活物質のパッケージ化：調製法および使用法
WO2011057267A1 (fr) * 2009-11-09 2011-05-12 National Jewish Health Composition de vaccin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KOSER M. L. ET AL: "Rabies virus nucleoprotein as a carrier for foreign antigens", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 101, no. 25, 22 June 2004 (2004-06-22), US, pages 9405 - 9410, XP055850378, ISSN: 0027-8424, Retrieved from the Internet <URL:https://www.pnas.org/content/pnas/101/25/9405.full.pdf> DOI: 10.1073/pnas.0403060101 *
LABARONNE ALICE ET AL: "Binding of RNA by the Nucleoproteins of Influenza Viruses A and B", VIRUSES, vol. 8, no. 9, 13 September 2016 (2016-09-13), pages 247, XP055850348, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035961/pdf/viruses-08-00247.pdf> DOI: 10.3390/v8090247 *
VREEDE F. T. ET AL: "Stabilization of Influenza Virus Replication Intermediates Is Dependent on the RNA-Binding but Not the Homo-Oligomerization Activity of the Viral Nucleoprotein", JOURNAL OF VIROLOGY, vol. 85, no. 22, 14 September 2011 (2011-09-14), US, pages 12073 - 12078, XP055850374, ISSN: 0022-538X, DOI: 10.1128/JVI.00695-11 *

Also Published As

Publication number Publication date
CU20200028A7 (es) 2021-11-04
CN115697394A (zh) 2023-02-03
MX2022013148A (es) 2022-11-16
WO2021213558A2 (fr) 2021-10-28
JP2023522118A (ja) 2023-05-26

Similar Documents

Publication Publication Date Title
Skene et al. Saponin-adjuvanted particulate vaccines for clinical use
ES2731899T3 (es) Composición de vacuna nasal contra la gripe
US8945590B2 (en) Enhancement of an immune response by administration of a cationic lipid-DNA complex (CLDC)
Salleh et al. Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2
MX2022009018A (es) Nanoparticulas lipidas.
ZA202300131B (en) Lipid nanoparticles
Xing et al. The recent advances in vaccine adjuvants
Schulze et al. New horizons in the development of novel needle-free immunization strategies to increase vaccination efficacy
WO2021213558A3 (fr) Nucléoprotéine virale et formulations la contenant
Kawai et al. Lipid nanoparticle with 1, 2-Di-O-octadecenyl-3-trimethylammonium-propane as a component lipid confers potent responses of Th1 cells and antibody against vaccine antigen
WO2011108521A1 (fr) Vaccin muqueux
US7943147B2 (en) dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
KR102654379B1 (ko) 신규한 핵산을 기반으로 하는 인플루엔자 백신 조성물
Zhang et al. Nanotechnology-driven advances in intranasal vaccine delivery systems against infectious diseases
Liu et al. Polymeric nanoparticles engineered as a vaccine adjuvant-delivery system
WO2004016281A1 (fr) Compositions de vaccins sous-cutanes contre la grippe contenant un facteur d&#39;adp-ribosylation
JP2010508308A (ja) 鳥インフルエンザウイルス感染の予防的治療のためのポリｉｃｌｃカプセル化リポソーム
Tomai et al. Toll-like receptor 7 and 8 agonists for vaccine adjuvant use
CN111344005A (zh) 经鼻乙型肝炎疫苗组合物及其制备方法
CN101754770B (zh) 皮内流感疫苗
Das et al. Emerging concepts in Leishmania vaccine adjuvants
US20220280631A1 (en) Viral pandemic vaccine
Baig et al. From Viral Vaccines to Messenger RNA Vaccines
HK40007838A (en) Nasal influenza vaccine composition
MX2025010536A (es) Nuevas formulaciones de nanoparticulas lipidicas para la administracion de acidos nucleicos

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2022563491

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21754904

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 21754904

Country of ref document: EP

Kind code of ref document: A2